Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association

Rhea-AI Summary

Viridian Therapeutics (NASDAQ: VRDN) has announced the presentation of two posters featuring preclinical data on its drug candidates, VRDN-001 and VRDN-002, at the 90th Annual Meeting of the American Thyroid Association from September 30 to October 3, 2021. The posters focus on VRDN-002's pharmacokinetic profile and clinical promise as a second-generation IGF-1R antagonist for Thyroid Eye Disease, and the characterization of VRDN-001 as a potent anti-IGF-1R inhibitory antibody. These developments signal ongoing advancements in treatment options for patients with thyroid eye disease.

Positive

• Presentation of preclinical data for VRDN-001 and VRDN-002 at a prominent conference, indicating active research and development.
• Demonstrated clinical promise of VRDN-002, which may enhance future treatment options for Thyroid Eye Disease.

Negative

• None.

WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, announced today that two posters featuring preclinical data on VRDN-001 and VRDN-002 are scheduled to be presented at the 90th Annual Meeting of the American Thyroid Association (ATA), which is being held from September 30^th through October 3^rd.

Poster Presentation Details:
Title:	VRDN-002, A Second-Generation Insulin Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody for Thyroid Eye Disease: Preclinical Pharmacokinetic Profile and Clinical Promise
Poster:	#37
Poster Session (1):	Thursday Poster Review Session
Time and Date:	Thursday, September 30, 2021, 12:15-1:00 p.m. EDT (Virtual Poster)
Poster Session (2):	Thursday Highlighted Posters Session #3
Time and Date:	Thursday, September 30, 2021, 4:00-5:00 p.m. EDT
Title:	Characterization of VRDN-001, a High Affinity and Potent anti-IGF-1R Inhibitory Antibody in Development for the Treatment of Thyroid Eye Disease
Poster #:	#187
Poster Session:	Saturday Poster Review Session
Time and Date:	Saturday, October 2, 2021, 1:00-2:00 p.m. EDT

About Viridian Therapeutics, Inc.

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED), a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.

Viridian Contacts:

Investors:
Dan Ferry
LifeSci Advisors
617-430-7576
IR@viridiantherapeutics.com

Media:
Darby Pearson
Verge Scientific Communications
703-587-0831
PR@viridiantherapeutics.com

Source: Viridian Therapeutics, Inc.

FAQ

What is the purpose of the posters presented by Viridian Therapeutics at the ATA meeting?

The posters aim to showcase preclinical data on VRDN-001 and VRDN-002, specifically their pharmacokinetic profiles and clinical potential for treating Thyroid Eye Disease.

When are the poster presentations scheduled during the American Thyroid Association meeting?

The poster presentations are scheduled for September 30, 2021, at 12:15-1:00 p.m. EDT and 4:00-5:00 p.m. EDT, and October 2, 2021, from 1:00-2:00 p.m. EDT.

What is the significance of VRDN-001 for patients with Thyroid Eye Disease?

VRDN-001 is a differentiated monoclonal antibody targeting IGF-1R, which is crucial for treating Thyroid Eye Disease, potentially reducing the need for multiple surgeries in severe cases.

How might the data presented impact the stock of Viridian Therapeutics?

Positive reception of the preclinical data at the conference could bolster investor confidence and potentially lead to an increase in stock price for VRDN.